Creative Planning Acquires 10,880 Shares of DexCom, Inc. (NASDAQ:DXCM)

Creative Planning grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 22.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 59,573 shares of the medical device company’s stock after acquiring an additional 10,880 shares during the period. Creative Planning’s holdings in DexCom were worth $3,994,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of DXCM. Team Hewins LLC boosted its holdings in DexCom by 3.4% in the 1st quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after purchasing an additional 83 shares during the period. Bleakley Financial Group LLC grew its position in DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock worth $951,000 after buying an additional 87 shares in the last quarter. Capital Insight Partners LLC increased its stake in DexCom by 2.5% during the 2nd quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock worth $418,000 after acquiring an additional 90 shares during the period. HM Payson & Co. raised its holdings in DexCom by 6.0% in the 1st quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after acquiring an additional 100 shares in the last quarter. Finally, State of Alaska Department of Revenue lifted its position in shares of DexCom by 0.3% during the 1st quarter. State of Alaska Department of Revenue now owns 41,830 shares of the medical device company’s stock valued at $5,801,000 after acquiring an additional 105 shares during the period. Institutional investors and hedge funds own 97.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on DXCM. Royal Bank of Canada decreased their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday. Morgan Stanley dropped their target price on shares of DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a report on Friday, July 26th. StockNews.com raised shares of DexCom from a “hold” rating to a “buy” rating in a report on Friday. Piper Sandler reissued an “overweight” rating and issued a $90.00 price objective on shares of DexCom in a research note on Monday, August 26th. Finally, Barclays decreased their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a research note on Monday, July 29th. Six research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $104.59.

Insiders Place Their Bets

In other news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other DexCom news, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,824 shares of company stock valued at $126,390. 0.30% of the stock is owned by insiders.

DexCom Stock Down 1.9 %

Shares of DexCom stock opened at $73.44 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The firm’s 50-day moving average is $70.11 and its two-hundred day moving average is $98.24. The stock has a market cap of $29.21 billion, a price-to-earnings ratio of 47.38, a PEG ratio of 2.16 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 24th. The medical device company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business had revenue of $994.20 million for the quarter, compared to analysts’ expectations of $991.55 million. As a group, research analysts expect that DexCom, Inc. will post 1.69 earnings per share for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.